CLRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cellectar Biosciences Inc (CLRB) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or trends to suggest immediate upside potential. It is better to hold off on investing until there are clearer signs of growth or momentum.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 69.014, and the moving averages are converging, suggesting no strong trend. The stock is trading near its resistance level (R1: 3.021), which could act as a barrier to further price increases.
The company has enrolled the first patient in a Phase 1b trial for CLR 121125 to treat triple-negative breast cancer, which could be a long-term positive catalyst if successful.
Weak financial performance with no revenue growth, negative EPS (-1.29), and a significant net loss (-$5.3M in Q4 2025). Analyst price targets have been reduced recently, and there are no significant insider or hedge fund trading trends.
In Q4 2025, revenue remained at $0 with no YoY growth. Net income improved by 124.81% YoY but remains negative at -$5.3M. EPS dropped by -23.21% YoY to -1.29. Gross margin is 0%, indicating no profitability.
Analysts remain optimistic with Buy ratings, but price targets have been reduced (e.g., Roth Capital lowered the target from $18 to $14). Maxim recently upgraded the stock to Buy with a $10 target.
